• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
IMMUNOMEDICS, INC - Product Pipeline Review - H2 2011 Product Image

IMMUNOMEDICS, INC - Product Pipeline Review - H2 2011

  • ID: 1964437
  • November 2011
  • 101 pages
  • Global Markets Direct

IMMUNOMEDICS, INC – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “IMMUNOMEDICS, INC - Product Pipeline Review - H2 2011” provides data on the IMMUNOMEDICS, INC’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, IMMUNOMEDICS, INC’s corporate website, SEC filings, investor presentations and featured press releases, both from IMMUNOMEDICS, INC and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- IMMUNOMEDICS, INC - Brief IMMUNOMEDICS, INC overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of IMMUNOMEDICS, INC human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
IMMUNOMEDICS, INC Snapshot
IMMUNOMEDICS, INC Overview
Key Information
Key Facts
IMMUNOMEDICS, INC – Research and Development Overview
Key Therapeutic Areas
IMMUNOMEDICS, INC – Pipeline Review
Pipeline Products by Stage of Development
IMMUNOMEDICS, INC – Pipeline Products Glance
IMMUNOMEDICS, INC Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
IMMUNOMEDICS, INC–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
IMMUNOMEDICS, INC – Drug Profiles
Clivatuzumab tetraxetan + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Epratuzumab + Chemotherapy
Product Description
Mechanism of Action
R&D Progress
Epratuzumab + R-CHOP
Product Description
Mechanism of Action
R&D Progress
Epratuzumab + Rituximab
Product Description
Mechanism of Action
R&D Progress
IMMU-107
Product Description
Mechanism of Action
R&D Progress
IMMU-114
Product Description
Mechanism of Action
R&D Progress
IMMU-130
Product Description
Mechanism of Action
R&D Progress
Lymphocide
Product Description
Mechanism of Action
R&D Progress
Milatuzumab
Product Description
Mechanism of Action
R&D Progress
Milatuzumab + Veltuzumab
Product Description
Mechanism of Action
R&D Progress
Milatuzumab-DOX
Product Description
Mechanism of Action
R&D Progress
TF2
Product Description
Mechanism of Action
R&D Progress
Veltuzumab
Product Description
Mechanism of Action
R&D Progress
Veltuzumab + Yttrium-90-Labelled-Epratuzumab
Product Description
Mechanism of Action
R&D Progress
IMMUNOMEDICS, INC – Pipeline Analysis
IMMUNOMEDICS, INC – Pipeline Products by Therapeutic Class
IMMUNOMEDICS, INC - Pipeline Products By Target
IMMUNOMEDICS, INC – Pipeline Products by Route of Administration
IMMUNOMEDICS, INC – Pipeline Products by Molecule Type
IMMUNOMEDICS, INC – Recent Pipeline Updates
IMMUNOMEDICS, INC - Dormant Projects
IMMUNOMEDICS, INC – Company Statement
IMMUNOMEDICS, INC – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 30, 2009: Immunomedics Reports Updated Results Of Milatuzumab In Dose-Escalation Study For Multiple Myeloma
Nov 29, 1999: Immunomedics Receives Comments From FDA on Leukoscan Imaging Product.
Aug 27, 2009: UCB And Immunomedics Announce Positive Results For Epratuzumab Phase IIb Study In Systemic Lupus Erythematosus
Jun 27, 2011: Immunomedics Receives Third Milestone Payment From Nycomed
Oct 24, 2007: Immunomedics's Milatuzumab Shows Promising Therapeutic Effects Alone And Combined With CD20 Antibody In Preclinical Studies
Aug 23, 1999: FDA Designates Orphan Drug Status For The Drug CEA-Cide Therapeutic
Sep 22, 2011: Immunomedics Announces Partial Clinical Hold On Clivatuzumab Tetraxetan Clinical Trial
Jun 21, 2010: Immunomedics Presents Results From Phase IIb EMBLEM Study Of Epratuzumab In Patients With Systemic Lupus Erythematosus
Jan 21, 2011: Immunomedics Reports Targeted Therapy For Advanced Pancreatic Cancer Improves Survival Rate
Apr 19, 2010: Immunomedics Reports Progress On Antibody-Drug Conjugate Development At Cancer Meeting
Jan 19, 2005: Immunomedics Announces Canadian Approval of LeukoScan.
May 18, 2009: Immunomedics Completes Phase I/II Study of Veltuzumab
Mar 18, 2008: Immunomedics, Inc.'s Milatuzumab Receives FDA Orphan Drug Designation For Therapy Of Multiple Myeloma
Oct 16, 2007: Immunomedics Announces The Granting OF U.S. Patent For Humanized PAM4 Monoclonal Antibody And Its Use In The Diagnosis And Therapy Of Pancreatic Cancer
Oct 16, 1996: Immunomedics' LeukoScan Recommended For European Approval
Aug 16, 2007: Immunomedics Reports Results Of Epratuzumab In Patients With Systemic Lupus Erythematosus
Jun 16, 2010: UCB And Immunomedics Report New Data From EMBLEM Study For Epratuzumab In Patients With Systemic Lupus Erythematosus
Jun 16, 2009: Immunomedics Reports New Antibody For Pretargeted Imaging And Therapy Of Colorectal Cancer
Jun 15, 2010: Immunomedics Doses First Patient In Phase I/II Study Of Milatuzumab-Doxorubicin Conjugate For Multiple Myeloma Therapy
Jun 15, 2009: Immunomedics Reports Updated Phase II Results With Radiolabeled Epratuzumab In Non-Hodgkin's Lymphoma
Apr 15, 2008: Immunomedics, Inc. Announces That Milatuzumab May Enhance Efficacies Of Therapeutics For Multiple Myeloma In Preclinical Studies
Oct 14, 2008: Immunomedics Announces U.S. Patents Awarded For Veltuzumab
Aug 14, 2009: Immunomedics Announces Milatuzumab-Doxorubicin Conjugate Recieves FDA Approval To Initiate Phase I/II Clinical Trial
Apr 14, 2000: Japanese Patent Awarded To Immunomedics for Non-Hodgkin's Lymphoma Therapeutic,
Feb 14, 1997: Immunomedics' LeukoScan Cleared for Marketing in Europe
May 13, 2010: Immunomedics To Present Results From Randomized Study Of Epratuzumab In Patients With Lupus At European Rheumatology Congress
Dec 11, 2006: Low Doses Of Humanized Anti-Cd20 Antibody Reported Active In Non-Hodgkin's Lymphoma
Jun 11, 2007: Immunomedics Presents Data On Epratuzumab At The 12th Congress of EHA
Dec 10, 2007: Immunomedics Drug Epratuzmab Plus Rituximab Produces Durable Complete Responses In Lymphoma
Aug 10, 2010: Immunomedics Receives Additional US Patent For Internalizing Anti-CD74 Antibodies And Methods Of Use
Jun 09, 2010: Immunomedics Announces Preclinical Results Of Pretargeted Imaging And Therapy Of Cancer With TF2
Jun 09, 2010: Immunomedics Presents New Antibody For Pretargeting Epithelial Cancers At 2010 Society Of Nuclear Medicine Annual Meeting
Dec 08, 2008: Immunomedics Reports Initial Results From Phase I/II Study of Veltuzumab
Dec 08, 2008: Immunomedics Reports Preliminary Results Of Milatuzumab In Multiple Myeloma Study
Jun 08, 2010: Immunomedics Reports Study Results Of TF2 In Patients With Colorectal Cancer
Jan 08, 2010: Immunomedics Receives US Patent Of Epratuzumab For The Treatment Of Systemic Lupus Erythematosus
Jun 07, 2011: Immunomedics Reports Final Survival Data With Yttrium-90-Labeled Clivatuzumab Tetraxetan And Low-Dose Gemcitabine In Advanced Pancreatic Cancer
Jun 07, 2010: Clivatuzumab Tetraxetan Shows Promising Results In Patients With Metastatic Pancreatic Cancer
Jun 07, 2010: Immunomedics Reports Updated Results Of Targeted Therapy For Advanced Pancreatic Cancer
Mar 07, 2002: Immunomedics Gains Approval Recommendation for LeukoScan in Australia.
Dec 06, 2010: Immunomedics Reports Positive Phase II Trial Results Of Epratuzumab + Rituximab In Follicular Lymphoma
Jun 06, 2011: Immunomedics Reports Phase I Clinical Results Of New Antibody-Directed Radiation Therapy For Colorectal Cancer
Jun 06, 2000: Clinical Results With Non-Hodgkin's Lymphoma (NHL) Therapeutic Reported by Immunomedics at Society of Nuclear Medicine Meeting.
Dec 05, 2010: Immunomedics Reports Progress With Milatuzumab Combination Therapy In Phase I/II Non-Hodgkin's Lymphoma Trial
Jun 05, 2009: Immunomedics Presents Results Of Phase I/II Study At The 14th Congress Of The European Hematology Association.
Jun 05, 2007: Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer
Jun 05, 2007: Immunomedics, INC Announces Promising Phase II Results With Epratuzumab And Chemotherapy In Children With Acute Lymphoblastic Leukemia
Jun 05, 2000: Immunomedics' Colorectal Cancer Therapy Phase II Results Of CEA-Cide Reported At Society Of Nuclear Medicine Meeting
Jun 04, 2007: Immunomedics Results For Epratuzumab And Chemotherapy In Children With Acute Lymphoblastic Leukemia
Jun 04, 2007: Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe And Effective In Colorectal Cancer With Liver Metastases
Feb 04, 2008: Immunomedics Initiates Phase I/II Study Of Veltuzumab
Dec 03, 2007: Immunomedics To Present Data On Epratuzumab At American Society Of Hematology 49th Annual Meeting
Jun 03, 2006: Repeated Radioimmunotherapy With 131I-Labetuzumab In Colorectal Cancer With Liver Metastases Found Safe And Well-Tolerated In Initial Phase II Study
Jun 03, 2006: Repeated Radioimmunotherapy With 131I-Labetuzumab In Colorectal Cancer With Liver Metastases Found Safe And Well-Tolerated In Initial Phase II Study
Dec 02, 2008: Immunomedics To Present Data On Epratuzumab At The 50th ASH Annual Meeting
Nov 02, 2011: Immunomedics Announces FDA Allows Resumption Of Clivatuzumab Tetraxetan Clinical Trial
Jun 02, 2008: Immunomedics Reports Clinical Results Of Epratuzumab In Lymphoma And Metastatic Colorectal Cancer
Jun 02, 2008: North Central Cancer Treatment Group Presents Phase II Study Results Of Epratuzumab Plus Rituximab And Chemotherapy Is Active, Safe, And Tolerable In Aggressive Lymphoma
Jun 02, 2008: North Central Cancer Treatment Group Presents Phase II Study Results Of Epratuzumab In Combination With Rituximab And Chemotherapy
May 02, 2011: Immunomedics Announces Encouraging Results From Single-Dose Escalation Study Of Y-90-Clivatuzumab Tetraxetan In Advanced Pancreatic Cancer
Dec 01, 1997: Immunomedics Partners with Eli Lilly for Product Distribution in Europe; LeukoScan Product to be Distributed First by Lilly
Aug 01, 2008: Immunomedics Announces Results Of Epratuzumab In Children With Acute Lymphoblastic Leukemia
Aug 01, 1995: Immunomedics files for European regulatory approval of infectious disease detection product, LeukoScan.
Jun 01, 2003: Anti-CEA Monoclonal Antibody Combined with Chemotherapy Demonstrates Positive Preclinical Results in Colon and Breast Cancers
Financial Deals Landscape
IMMUNOMEDICS, INC, Deals Summary
IMMUNOMEDICS, INC, Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Immunomedics Enters Into Licensing Agreement With Alexis Biotech
Immunomedics Enters Into Licensing Agreement With Nycomed International
Immunomedics Enters Into Worldwide Licensing Agreement With UCB
Equity Offering
Immunomedics Files Shelf Registration Statement For Public Offering Of $151 Million
Immunomedics Completes Private Placement Of $24 Million
Immunomedics Completes A Private Placement Of $15 Million
Debt Offering
Immunomedics Completes A Private Placement Of 5% Senior Convertible Notes For $37 Million
Immunomedics Completes Public Offering Of 3.25% Convertible Senior Notes For $10 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
IMMUNOMEDICS, INC – Pipeline by Therapy Area and Indication, H2 2011
IMMUNOMEDICS, INC – Pipeline by Stage of Development, H2 2011
IMMUNOMEDICS, INC - Phase II, H2 2011
IMMUNOMEDICS, INC - Phase I, H2 2011
IMMUNOMEDICS, INC - Pipeline By Therapeutic Class, H2 2011
IMMUNOMEDICS, INC - Pipeline By Target, H2 2011
IMMUNOMEDICS, INC – Pipeline By Route of Administration, H2 2011
IMMUNOMEDICS, INC – Pipeline By Molecule Type, H2 2011
IMMUNOMEDICS, INC – Recent Pipeline Updates, H2 2011
IMMUNOMEDICS, INC - Dormant Developmental Projects, 2010
IMMUNOMEDICS, INC, Other Locations
IMMUNOMEDICS, INC, Subsidiaries
IMMUNOMEDICS, INC, Deals Summary
Immunomedics Enters Into Licensing Agreement With Alexis Biotech
Immunomedics Enters Into Licensing Agreement With Nycomed International
Immunomedics Enters Into Worldwide Licensing Agreement With UCB
Immunomedics Files Shelf Registration Statement For Public Offering Of $151 Million
Immunomedics Completes Private Placement Of $24 Million
Immunomedics Completes A Private Placement Of $15 Million
Immunomedics Completes A Private Placement Of 5% Senior Convertible Notes For $37 Million
Immunomedics Completes Public Offering Of 3.25% Convertible Senior Notes For $10 Million

List of Figures
IMMUNOMEDICS, INC – Pipeline by Therapy Area and Indication, H2 2011
IMMUNOMEDICS, INC – Pipeline by Stage of Development, H2 2011
IMMUNOMEDICS, INC – Pipeline By Therapeutic Class, H2 2011
IMMUNOMEDICS, INC - Pipeline By Target, H2 2011
IMMUNOMEDICS, INC – Pipeline By Route of Administration, H2 2011
IMMUNOMEDICS, INC – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos